MDRNA Inks Early-Stage Collaboration Related to miRNA Therapies | GenomeWeb

MDRNA said this week that it has signed a new early collaborative effort with an undisclosed company focused on microRNA-directed oncology therapies.

According to the company, the arrangement will focus on the use of MDRNA's DiLA2 delivery technology with proprietary miRNAs in "experimental oncology models." Additional terms of the deal were not disclosed.

The DiLA2 technology relates to synthetic di-alklylated amino acid compounds used to make liposomal delivery formulations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.